Nasdaq, S&P 500 Futures Fall Ahead Of CPI Data, Oracle Earnings: Why SMCI, TSM, CRWV, YYGH Are Keeping Traders Engaged Today

SMCI shares fell about 10% premarket after announcing a $7 billion financing package to fund its AI infrastructure backlog.

Likely choppy to downside bias into the next session as traders price financing terms and dilution risk.

The article cites a same-day premarket drop tied directly to a large financing package, which typically drives immediate risk repricing.

Oracle is trending ahead of fiscal Q4 earnings, with investors focused on whether cloud growth can justify heavy AI capex.

Volatile reaction expected after the close, with direction dependent on cloud growth and AI capex commentary.

The piece frames a specific upcoming earnings catalyst and the key metric trade-off traders will use.

TSM stock fell about 2% premarket after reporting a 30% YoY surge in May sales, while AI chip regulation concerns rattled investors.

Near-term downside or range-bound trading until regulation clarity improves, despite the sales beat.

The article links the premarket decline to regulation concerns, not the sales print itself.

CoreWeave extended its slide after reports its co-founders and Magnetar Financial unloaded billions of shares post lockup.

Downside pressure likely to persist while selling pressure remains the dominant narrative.

The article ties the continued slide to a concrete post-lockup selling report, which can quickly affect float and sentiment.

YY Group Holdings surged over 55% premarket after unveiling an Nvidia-powered humanoid robot program for service operations.

High-volatility continuation possible, but risk of sharp mean reversion is elevated after a large premarket spike.

The article provides a same-day magnitude move and a specific catalyst tied to the company’s program.

Eli Lilly gained attention after the FDA approved a new maintenance dosing for its atopic dermatitis drug, Ebglyss.

Supportive near-term bid likely, with follow-through depending on market expectations for uptake and label expansion.

The approval is a concrete regulatory event that can re-rate revenue expectations and sentiment quickly.

Summit Therapeutics fell nearly 6% premarket after an equity offering.

Likely continued weakness or elevated volatility until offering terms are digested.

The article directly links the premarket drop to the equity offering, a classic near-term negative catalyst.

Robinhood is in focus after CEO Vlad Tenev said the firm secured a green light to underwrite IPOs, plus a director bought $20.2M shares.

Moderate upside bias possible, but reaction likely depends on how traders interpret underwriting scope and timing.

The article mixes a strategic statement with an insider purchase, but provides no underwriting economics or timing details.